Abbott Laboratories Total Long Term Liabilities 2010-2024 | ABT
Abbott Laboratories total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- Abbott Laboratories total long term liabilities for the quarter ending June 30, 2024 were $19.697B, a 8.81% decline year-over-year.
- Abbott Laboratories total long term liabilities for 2023 were $20.546B, a 6.8% decline from 2022.
- Abbott Laboratories total long term liabilities for 2022 were $22.044B, a 15.43% decline from 2021.
- Abbott Laboratories total long term liabilities for 2021 were $26.067B, a 5.68% decline from 2020.
| Abbott Laboratories Annual Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2023 | $20,546 |
| 2022 | $22,044 |
| 2021 | $26,067 |
| 2020 | $27,638 |
| 2019 | $25,723 |
| 2018 | $27,439 |
| 2017 | $36,240 |
| 2016 | $25,289 |
| 2015 | $10,735 |
| 2014 | $9,101 |
| 2013 | $8,179 |
| 2012 | $27,142 |
| 2011 | $20,271 |
| 2010 | $20,546 |
| 2009 | $16,345 |
| Abbott Laboratories Quarterly Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2024-06-30 | $19,697 |
| 2024-03-31 | $19,403 |
| 2023-12-31 | $20,546 |
| 2023-09-30 | $21,354 |
| 2023-06-30 | $21,600 |
| 2023-03-31 | $22,032 |
| 2022-12-31 | $22,044 |
| 2022-09-30 | $23,552 |
| 2022-06-30 | $25,094 |
| 2022-03-31 | $25,731 |
| 2021-12-31 | $26,067 |
| 2021-09-30 | $26,290 |
| 2021-06-30 | $26,626 |
| 2021-03-31 | $26,535 |
| 2020-12-31 | $27,638 |
| 2020-09-30 | $27,191 |
| 2020-06-30 | $27,019 |
| 2020-03-31 | $25,542 |
| 2019-12-31 | $25,723 |
| 2019-09-30 | $26,029 |
| 2019-06-30 | $27,471 |
| 2019-03-31 | $27,368 |
| 2018-12-31 | $27,439 |
| 2018-09-30 | $27,963 |
| 2018-06-30 | $28,690 |
| 2018-03-31 | $30,297 |
| 2017-12-31 | $36,240 |
| 2017-09-30 | $32,095 |
| 2017-06-30 | $32,560 |
| 2017-03-31 | $32,694 |
| 2016-12-31 | $25,289 |
| 2016-09-30 | $10,280 |
| 2016-06-30 | $10,363 |
| 2016-03-31 | $10,402 |
| 2015-12-31 | $10,735 |
| 2015-09-30 | $11,751 |
| 2015-06-30 | $11,814 |
| 2015-03-31 | $11,901 |
| 2014-12-31 | $9,101 |
| 2014-09-30 | $8,698 |
| 2014-06-30 | $7,918 |
| 2014-03-31 | $7,987 |
| 2013-12-31 | $8,179 |
| 2013-09-30 | $9,013 |
| 2013-06-30 | $9,556 |
| 2013-03-31 | $9,597 |
| 2012-12-31 | $27,142 |
| 2012-09-30 | $19,867 |
| 2012-06-30 | $20,167 |
| 2012-03-31 | $20,086 |
| 2011-12-31 | $20,271 |
| 2011-09-30 | $19,525 |
| 2011-06-30 | $19,695 |
| 2011-03-31 | $19,706 |
| 2010-12-31 | $20,546 |
| 2010-09-30 | $20,307 |
| 2010-06-30 | $18,698 |
| 2010-03-31 | $17,163 |
| 2009-12-31 | $16,345 |
| 2009-09-30 | $15,948 |
| 2009-06-30 | $15,668 |
| 2009-03-31 | $15,684 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $199.879B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $137.705B | 32.18 |
| Boston Scientific (BSX) | United States | $121.595B | 37.03 |
| Medtronic (MDT) | Ireland | $113.026B | 16.82 |
| EssilorLuxottica (ESLOY) | France | $104.378B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.118B | 35.17 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.437B | 0.00 |
| ResMed (RMD) | United States | $34.974B | 30.79 |
| Koninklijke Philips (PHG) | Netherlands | $29.016B | 22.05 |
| Terumo (TRUMY) | Japan | $27.876B | 39.37 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.644B | 13.63 |
| Baxter (BAX) | United States | $20.086B | 13.62 |
| Insulet (PODD) | United States | $16.555B | 69.65 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.426B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.489B | 31.44 |
| Demant (WILYY) | Denmark | $9.197B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.672B | 32.44 |
| Lantheus Holdings (LNTH) | United States | $7.508B | 18.02 |
| ICU Medical (ICUI) | United States | $4.304B | 41.08 |
| TG Therapeutics (TGTX) | United States | $3.909B | 41.39 |
| Haemonetics (HAE) | United States | $3.870B | 19.14 |
| Perrigo (PRGO) | Ireland | $3.841B | 12.14 |
| GN Store Nord (GNNDY) | Denmark | $3.758B | 22.64 |
| Neogen (NEOG) | United States | $3.736B | 39.18 |
| Prestige Consumer Healthcare (PBH) | United States | $3.644B | 18.16 |
| Envista Holdings (NVST) | United States | $3.298B | 17.60 |
| QuidelOrtho (QDEL) | United States | $3.108B | 19.59 |
| Agios Pharmaceuticals (AGIO) | United States | $2.591B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.311B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.171B | 36.43 |
| LeMaitre Vascular (LMAT) | United States | $1.996B | 53.20 |
| AdaptHealth (AHCO) | United States | $1.524B | 11.00 |
| InMode (INMD) | Israel | $1.466B | 9.34 |
| Warby Parker (WRBY) | United States | $1.466B | 0.00 |
| AtriCure (ATRC) | United States | $1.363B | 0.00 |
| Owens & Minor (OMI) | United States | $1.219B | 9.41 |
| Verano Holdings (VRNOF) | United States | $1.114B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.094B | 0.00 |
| Evolus (EOLS) | United States | $1.023B | 0.00 |
| PetIQ (PETQ) | United States | $0.920B | 23.32 |
| Phibro Animal Health (PAHC) | United States | $0.897B | 18.61 |
| National Vision Holdings (EYE) | United States | $0.864B | 27.48 |
| Cresco Labs (CRLBF) | United States | $0.801B | 0.00 |
| Surmodics (SRDX) | United States | $0.561B | 119.09 |
| Quanterix (QTRX) | United States | $0.543B | 0.00 |
| ZimVie (ZIMV) | United States | $0.454B | 42.23 |
| VAREX IMAGING (VREX) | United States | $0.451B | 13.62 |
| Valneva SE (VALN) | France | $0.422B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.406B | 0.00 |
| Jin Medical (ZJYL) | China | $0.397B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.333B | 0.00 |
| Cerus (CERS) | United States | $0.330B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.321B | 8.29 |
| Aurora Cannabis (ACB) | Canada | $0.320B | 0.00 |
| Biote (BTMD) | United States | $0.319B | 14.70 |
| Viemed Healthcare (VMD) | United States | $0.287B | 30.79 |
| Sanara MedTech (SMTI) | United States | $0.272B | 0.00 |
| Zynex (ZYXI) | United States | $0.260B | 45.44 |
| Utah Medical Products (UTMD) | United States | $0.234B | 15.52 |
| Ayr Wellness (AYRWF) | United States | $0.232B | 0.00 |
| Omeros (OMER) | United States | $0.228B | 0.00 |
| MacroGenics (MGNX) | United States | $0.207B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.196B | 0.00 |
| High Tide (HITI) | Canada | $0.170B | 70.33 |
| Capricor Therapeutics (CAPR) | United States | $0.167B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.153B | 20.62 |
| Brainsway (BWAY) | Israel | $0.140B | 168.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.135B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.125B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.124B | 0.00 |
| Veru (VERU) | United States | $0.113B | 0.00 |
| Fonar (FONR) | United States | $0.110B | 11.15 |
| Jushi Holdings (JUSHF) | United States | $0.103B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.099B | 24.20 |
| InterCure (INCR) | Israel | $0.085B | 14.31 |
| Safety Shot (SHOT) | United States | $0.082B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.077B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.076B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.075B | 0.00 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.056B | 3.63 |
| Exagen (XGN) | United States | $0.049B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.036B | 0.00 |
| Bright Green (BGXX) | United States | $0.028B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.011B | 0.00 |
| Agape ATP (ATPC) | $0.008B | 0.00 | |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 20.47 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |